Literature DB >> 22233449

Glial modulators: a novel pharmacological approach to altering the behavioral effects of abused substances.

Ziva D Cooper1, Jermaine D Jones, Sandra D Comer.   

Abstract

INTRODUCTION: Commonly abused drugs including opioids, stimulants and alcohol activate glia cells, an effect that has been identified across species. Glia, specifically astrocytes and microglia, have been shown to contribute directly to behaviors predictive of the abuse liability of these drugs. Although still in its infancy, research investigating the effects of pharmacological modulation of glial activity on these behaviors has provided encouraging findings suggesting glial cell modulators as potential pharmacotherapies for substance-use disorders. AREAS COVERED: This review first explores the evidence establishing glial-mediated modulations of behaviors associated with opioid, stimulant and alcohol exposure, with emphasis placed on the neuroanatomical substrates for these effects. Next, neurobiological and behavioral studies evaluating the ability of glial cell modulators to prevent and reverse the effects of these abused substances will be considered. Finally, the potential clinical efficacy of glial cell modulators as a novel pharmacological approach to treat substance-use disorders in relation to currently available, conventional pharmacotherapies will be discussed. EXPERT OPINION: Though the relationship between drug-induced glial activity and behaviors indicative of drug abuse and dependence is not yet fully elucidated, the evidence for the association continues to grow. The use of glial modulators as pharmacological tools to investigate this relationship has also yielded findings supporting their potential clinical efficacy for treating substance-use disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22233449      PMCID: PMC3314383          DOI: 10.1517/13543784.2012.651123

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  75 in total

1.  Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats.

Authors:  Vasudeva Raghavendra; Flobert Y Tanga; Joyce A DeLeo
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

2.  The involvement of glial cells in the development of morphine tolerance.

Authors:  P Song; Z Q Zhao
Journal:  Neurosci Res       Date:  2001-03       Impact factor: 3.304

3.  The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse.

Authors:  Patrick M Beardsley; Keith L Shelton; Elizabeth Hendrick; Kirk W Johnson
Journal:  Eur J Pharmacol       Date:  2010-04-23       Impact factor: 4.432

Review 4.  Functional roles of microglia in the brain.

Authors:  K Nakajima; S Kohsaka
Journal:  Neurosci Res       Date:  1993-08       Impact factor: 3.304

Review 5.  The role of microglia and macrophages in the pathophysiology of the CNS.

Authors:  G Stoll; S Jander
Journal:  Prog Neurobiol       Date:  1999-06       Impact factor: 11.685

6.  Morphine-induced chemotaxis and brain-derived neurotrophic factor expression in microglia.

Authors:  Naoko Takayama; Hiroshi Ueda
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

7.  Glial fibrillary acidic protein and the mesolimbic dopamine system: regulation by chronic morphine and Lewis-Fischer strain differences in the rat ventral tegmental area.

Authors:  D Beitner-Johnson; X Guitart; E J Nestler
Journal:  J Neurochem       Date:  1993-11       Impact factor: 5.372

8.  Methamphetamine causes microglial activation in the brains of human abusers.

Authors:  Yoshimoto Sekine; Yasuomi Ouchi; Genichi Sugihara; Nori Takei; Etsuji Yoshikawa; Kazuhiko Nakamura; Yasuhide Iwata; Kenji J Tsuchiya; Shiro Suda; Katsuaki Suzuki; Masayoshi Kawai; Kiyokazu Takebayashi; Shigeyuki Yamamoto; Hideo Matsuzaki; Takatoshi Ueki; Norio Mori; Mark S Gold; Jean L Cadet
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

9.  Evidence that opioids may have toll-like receptor 4 and MD-2 effects.

Authors:  Mark R Hutchinson; Yingning Zhang; Mitesh Shridhar; John H Evans; Madison M Buchanan; Tina X Zhao; Peter F Slivka; Benjamen D Coats; Niloofar Rezvani; Julie Wieseler; Travis S Hughes; Kyle E Landgraf; Stefanie Chan; Stephanie Fong; Simon Phipps; Joseph J Falke; Leslie A Leinwand; Steven F Maier; Hang Yin; Kenner C Rice; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2009-08-11       Impact factor: 7.217

Review 10.  Visualising microglial activation in vivo.

Authors:  Richard B Banati
Journal:  Glia       Date:  2002-11       Impact factor: 8.073

View more
  19 in total

Review 1.  The role of glia in stress: polyamines and brain disorders.

Authors:  Serguei N Skatchkov; Michel A Woodbury-Fariña; Misty Eaton
Journal:  Psychiatr Clin North Am       Date:  2014-11-25

2.  SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation.

Authors:  Matthew J Robson; Ryan C Turner; Zachary J Naser; Christopher R McCurdy; James P O'Callaghan; Jason D Huber; Rae R Matsumoto
Journal:  Exp Neurol       Date:  2014-02-06       Impact factor: 5.330

Review 3.  Glial modulators as potential treatments of psychostimulant abuse.

Authors:  Patrick M Beardsley; Kurt F Hauser
Journal:  Adv Pharmacol       Date:  2014

4.  Cocaine evokes a profile of oxidative stress and impacts innate antiviral response pathways in astrocytes.

Authors:  Irma E Cisneros; Mert Erdenizmenli; Kathryn A Cunningham; Slobodan Paessler; Kelly T Dineley
Journal:  Neuropharmacology       Date:  2018-03-23       Impact factor: 5.250

Review 5.  Addiction science: Uncovering neurobiological complexity.

Authors:  N D Volkow; R D Baler
Journal:  Neuropharmacology       Date:  2013-05-18       Impact factor: 5.250

6.  Chronic administration of the methylxanthine propentofylline impairs reinstatement to cocaine by a GLT-1-dependent mechanism.

Authors:  Kathryn J Reissner; Robyn M Brown; Sade Spencer; Phuong K Tran; Charles A Thomas; Peter W Kalivas
Journal:  Neuropsychopharmacology       Date:  2013-08-29       Impact factor: 7.853

7.  Cocaine Self-Administration and Extinction Leads to Reduced Glial Fibrillary Acidic Protein Expression and Morphometric Features of Astrocytes in the Nucleus Accumbens Core.

Authors:  Michael D Scofield; Hao Li; Benjamin M Siemsen; Kati L Healey; Phuong K Tran; Nicholas Woronoff; Heather A Boger; Peter W Kalivas; Kathryn J Reissner
Journal:  Biol Psychiatry       Date:  2015-12-31       Impact factor: 13.382

8.  Ibudilast (AV411), and its AV1013 analog, reduce HIV-1 replication and neuronal death induced by HIV-1 and morphine.

Authors:  Nazira El-Hage; Myosotys Rodriguez; Elizabeth M Podhaizer; Shiping Zou; Seth M Dever; Sarah E Snider; Pamela E Knapp; Patrick M Beardsley; Kurt F Hauser
Journal:  AIDS       Date:  2014-06-19       Impact factor: 4.177

9.  The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users.

Authors:  Jermaine D Jones; Maria A Sullivan; Jeanne M Manubay; Shanthi Mogali; Verena E Metz; Roberto Ciccocioppo; Sandra D Comer
Journal:  Physiol Behav       Date:  2015-10-09

10.  SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation.

Authors:  Matthew J Robson; Ryan C Turner; Zachary J Naser; Christopher R McCurdy; Jason D Huber; Rae R Matsumoto
Journal:  Exp Neurol       Date:  2013-04-28       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.